Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression

Leukemia and Lymphoma

Volumn 50, Issue 12, 2009, Pages 2038-2048

  Kumar, Sekar Ashok ^a,b   Hu, Xiaojie ^a,b   Brown, Michelle ^a   Kuschak, Brenda ^a   Hernandez, Tiffany A ^a   Johnston, James B ^a,c   Gibson, Spencer B ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c CANCERCARE MANITOBA   (Canada)

Author keywords

And chronic lymphocytic leukemia (CLL); Apoptosis; LPA; VEGF

Indexed keywords

LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION;

AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; RECEPTORS, LYSOPHOSPHATIDIC ACID; RECEPTORS, PURINERGIC P2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIDARABINE;

EID: 72949100769     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903275586     Document Type: Article

References (59)

1. Bannerji R, Byrd JC. Update on the biology of chronic lymphocytic leukemia. Curr Opin Oncol 2000;12:22-29.
2. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: A bird of a different feather. J Clin Oncol 1999;17:399-408.
3. Johnston J. Chronic lymphocytic leukemia. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, editors. Wintrobe's clinical hematology. Baltimore, MD: Williams and Wilkens; 1999. pp 2405-2427.
4. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001;98:3050-3057.
5. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-2663.
6. Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100:1795-1801.
7. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757.
8. Jones DT, Ganeshaguru K, Anderson RJ, et al. Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil-and radiationinduced apoptosis. Blood 2003;101:3174-3180.
9. Rosskopf D, Daelman W, Busch S, et al. Growth factor-like action of lysophosphatidic acid on human B lymphoblasts. Am J Physiol 1998;274(6 Part 1):C1573-C1582.
10. Hu X, Haney N, Kropp D, Kabore AF, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB. J Biol Chem 2005;280:9498-9508.
11. Deng W, Balazs L, Wang DA, Van Middlesworth L, Tigyi G, Johnson LR. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation-and chemotherapyinduced apoptosis. Gastroenterology 2002;123:206-216.
12. Deng W, Wang DA, Gosmanova E, Johnson LR, Tigyi G. LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway. Am J Physiol Gastrointest Liver Physiol 2003;284:G821-G829.
13. Fang X, Yu S, LaPushin R, et al. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 2000;352(Part 1):135-143.
14. Goetzl EJ, Lee H, Dolezalova H, et al. Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann NY Acad Sci 2000;905:177-187.
15. Iglesias J, Abernethy VE, Wang Z, Lieberthal W, Koh JS, Levine JS. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am J Physiol 1999;277(5 Part 2):F711-F722.
16. Weiner JA, Chun J. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc Natl Acad Sci USA 1999;96:5233-5238.
17. Harrison SM, Reavill C, Brown G, et al. LPA(1) receptordeficient mice have phenotypic changes observed in psychiatric disease. Mol Cell Neurosci 2003;24:1170-1179.
18. Takuwa Y, Takuwa N, Sugimoto N. The Edg family G protein-coupled receptors for lysophospholipids: Their signaling properties and biological activities. J Biochem (Tokyo) 2002;131:767-771.
19. Fang X, Gaudette D, Furui T, et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad Sci 2000;905:188-208.
20. Sardar VM, Bautista DL, Fischer DJ, et al. Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim Biophys Acta 2002;1582(1-3):309-317.
21. Lee Z, Cheng CT, Zhang H, et al. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 2008;19:5435-5445.
22. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13-and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006;281:23589-32397
23. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003;278:25600-25606.
24. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA 2000;97:13384-13389.
25. Fukushima N, Chun J. The LPA receptors. Prostaglandins Other Lipid Mediat 2001;64:21-32.
26. Shida D, Kitayama J, Yamaguchi H, et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 2003;63:1706-1711.
27. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10.
28. Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006;33:174-185.
29. Kay NE. The angiogenic status of B-CLL B cells: Role of the VEGF receptors. Leuk Res 2004;28:221-222.
30. Giles FJ. The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies. Oncologist 2001;6(Suppl 5):32-39.
31. Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;107:605-610.
32. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 2005;19:524-530.
33. Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 2003;17:1961-1966.
34. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149-1159.
35. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
36. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004;28:243-248.
37. Nowakowski GS, Mukhopadhyay D, Wu X, Kay NE. Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells. Leuk Res 2008;32:1634-1636.
38. Lee J, Park SY, Lee EK, et al. Activation of hypoxia-inducible factor-1{a} is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res 2006;12:6351-6358.
39. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al. Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006;20:1759-1766.
40. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-kB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002;73:237-243.
41. Begleiter A, Verburg L, Ashique A, et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-barabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995;9:1875-1881.
42. Johnston JB, Kabore AF, Strutinsky J, et al. Role of the TRAIL/APO2-L death receptors in chlorambucil-and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003;22:8356-8369.
43. Oudijk EJ, Nijhuis EH, Zwank MD, et al. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax 2005;60:538-544.
44. Gresch O, Engel FB, Nesic D, et al. New non-viral method for gene transfer into primary cells. Methods 2004;33:151-163.
45. Hu YL, TeeMK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001;93:762-768.
46. Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signal 2008;20:1198-1208.
47. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: Implication for apoptosis resistance. Leukemia 2005;19:513-523.
48. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol 1996;16:4604-4613.
49. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 30-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-5886.
50. Faderl S, Do KA, Johnson MM, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 2005;106:4303-4307.
51. de Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C. Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 2006;33(6 Suppl 11):S42-S45.
52. Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des 2006;12:387-394.
53. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004;104:788-794.
54. Shanafelt TD, Lee YK, Call TG, et al. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 2006;30:707-712.
55. Sasagawa T, Okita M, Murakami J, Kato T, Watanabe A. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids 1999;34:17-21.
56. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. J Am Med Assoc 1998;280:719-723.
57. Frankel A, Mills GB. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin Cancer Res 1996; 2:1307-1313.
58. Kang YC, Kim KM, Lee KS, et al. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ 2004;11:1287-1298.
59. Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J. Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat Neurosci 2003;6:1292-1299.